BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grund T, Neumann ID. Brain neuropeptide S: via GPCR activation to a powerful neuromodulator of socio-emotional behaviors. Cell Tissue Res 2019;375:123-32. [PMID: 30112573 DOI: 10.1007/s00441-018-2902-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Peter HL, Giglberger M, Frank J, Streit F, Zänkert S, Kreuzpointner L, Rietschel M, Kudielka BM, Wüst S. The association between genetic variability in the NPS/NPSR1 system and chronic stress responses: A gene-environment-(quasi-) experiment. Psychoneuroendocrinology 2022;144:105883. [PMID: 35914393 DOI: 10.1016/j.psyneuen.2022.105883] [Reference Citation Analysis]
2 Ryan M, Ryznar R. The Molecular Basis of Resilience: A Narrative Review. Front Psychiatry 2022;13:856998. [DOI: 10.3389/fpsyt.2022.856998] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tobinski AM, Rappeneau V. Role of the Neuropeptide S System in Emotionality, Stress Responsiveness and Addiction-Like Behaviours in Rodents: Relevance to Stress-Related Disorders. Pharmaceuticals (Basel) 2021;14:780. [PMID: 34451877 DOI: 10.3390/ph14080780] [Reference Citation Analysis]
4 Cherik F, Lepage M, Remerand G, Francannet C, Delabaere A, Salaun G, Pebrel-Richard C, Gouas L, Vago P, Tchirkov A, Goumy C. Further refining the critical region of 10q26 microdeletion syndrome: A possible involvement of INSYN2 and NPS in the cognitive phenotype. Eur J Med Genet 2021;64:104287. [PMID: 34252586 DOI: 10.1016/j.ejmg.2021.104287] [Reference Citation Analysis]
5 Park S, Flüthmann P, Wolany C, Goedecke L, Spenner HM, Budde T, Pape HC, Jüngling K. Neuropeptide S Receptor Stimulation Excites Principal Neurons in Murine Basolateral Amygdala through a Calcium-Dependent Decrease in Membrane Potassium Conductance. Pharmaceuticals (Basel) 2021;14:519. [PMID: 34072275 DOI: 10.3390/ph14060519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pałasz A, Żarczyński P, Bogus K, Mordecka-Chamera K, Della Vecchia A, Skałbania J, Worthington JJ, Krzystanek M, Żarczyńska M. Modulatory effect of olanzapine on SMIM20/phoenixin, NPQ/spexin and NUCB2/nesfatin-1 gene expressions in the rat brainstem. Pharmacol Rep 2021;73:1188-94. [PMID: 33928538 DOI: 10.1007/s43440-021-00267-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pałasz A, Menezes IC, Worthington JJ. The role of brain gaseous neurotransmitters in anxiety. Pharmacol Rep 2021;73:357-71. [PMID: 33713315 DOI: 10.1007/s43440-021-00242-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bengoetxea X, Goedecke L, Remmes J, Blaesse P, Grosch T, Lesting J, Pape HC, Jüngling K. Human-Specific Neuropeptide S Receptor Variants Regulate Fear Extinction in the Basal Amygdala of Male and Female Mice Depending on Threat Salience. Biol Psychiatry 2021;90:145-55. [PMID: 33902914 DOI: 10.1016/j.biopsych.2021.02.967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
9 Gupta PR, Prabhavalkar K. Combination therapy with neuropeptides for the treatment of anxiety disorder. Neuropeptides 2021;86:102127. [PMID: 33607407 DOI: 10.1016/j.npep.2021.102127] [Reference Citation Analysis]
10 Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019;204:107402. [PMID: 31470029 DOI: 10.1016/j.pharmthera.2019.107402] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 14.7] [Reference Citation Analysis]
11 Grinevich V, Jirikowski GF. Towards new frontiers in neuroendocrinology: A tribute to Peter H. Seeburg. Cell Tissue Res 2019;375:1-2. [DOI: 10.1007/s00441-018-2952-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]